Echo Therapeutics has reported positive results of Symphony tCGM system's trial in elective cardiac surgery patients.
The study, which enrolled fifteen adult patients, was designed to assess the performance of Symphony tCGM system in the critical care setting and was performed at Tufts Medical Center in Boston, Massachusetts, US.
The skin of each patient was prepared using Prelude and a Symphony tCGM biosensor was applied to the skin site prior to surgery.
Reference blood samples were taken from arterial line catheters at 30-minute intervals and measured on a YSI 2300 STAT Plus glucose analyzer.
The results demonstrated that Symphony read glucose levels accurately, with a mean absolute relative difference or error rate of 12.3%.
Study principal investigator and Tufts Medical Center surgical intensive care units director Stanley Nasraway said Echo’s study has produced compelling clinical evidence that the continuous technology can be used for safely sustaining glucose levels within a target range in acutely ill patients.
"Given the ease of use of this system and the potential cost-savings to hospitals it is likely that Symphony would transition with critically ill patients from the Intensive Care Units to the hospital general floors where better glucose control through technology-assistance is desperately needed in a setting of fewer nursing resources," Nasraway added.